Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor. | May 12, 2023
Impel Pharmaceuticals (NASDAQ:IMPL – Get Rating) is scheduled to release its earnings data before the market opens on Friday, May 12th. Impel Pharmaceuticals Stock Up 12.6 % NASDAQ IMPL opened at $2.60 on Friday. The company has a market capitalization of $61.75 million, a P/E ratio of -0.57 and a beta of -0.26. Impel Pharmaceuticals […]
SEATTLE, May 05, 2023 Impel Pharmaceuticals Inc. , a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs,. | May 5, 2023
Impel Pharmaceuticals Inc. (NASDAQ:IMPL – Get Rating) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 389,700 shares, a growth of 17.1% from the March 31st total of 332,800 shares. Based on an average daily trading volume, of 42,800 shares, […]
Impel Pharmaceuticals Inc. (NASDAQ:IMPL – Get Rating) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 389,700 shares, a growth of 17.1% from the March 31st total of 332,800 shares. Currently, 5.1% of the company’s shares are sold short. Based on an average […]